debate: what is the optimal timing for egfr-targeted therapy? - only upon progression
Published 11 years ago • 53 plays • Length 2:42Download video MP4
Download video MP3
Similar videos
-
10:05
debate: what is the optimal timing for egfr-targeted therapy? - favor maintenance
-
10:06
debate: what is the optimal timing for egfr-targeted therapy? - favor frontline therapy
-
8:37
debate: adjuvant egfr-directed therapy for patients with early stage nsclc? - yes
-
7:55
debate: what is the appropriate use of extended therapy? - continuation maintenance
-
10:45
debate: adjuvant egfr-directed therapy for patients with early stage nsclc? - no
-
41:23
multimodal management of early-stage nsclc: egfr-targeted therapy in perioperative settings
-
9:27
debate: what is the appropriate use of extended therapy? - switch maintenance therapy
-
20:24
targeted treatment with egfr tkis: front line options
-
15:22
debate | dr t p sahoo | is osimertinib the best option for first line treatment of egfr mutant
-
5:53
targeted therapy in non-small cell lung cancer
-
17:55
front-line targeted therapy for advanced egfr-positive disease
-
11:54
debate: targeted therapy for ras/braf wt left sided colon cancers - bevacizumab or egfr antibodies
-
20:07
acquired egfr resistance: what are the current therapeutic strategies?
-
33:52
keynote lecture: targeted therapies in lung cancer 2.0 – advances and promises
-
11:51
debate: what is the optimal therapy for gej cancers? - cross
-
28:22
gracecast-088_lung-cancer_challenging cases in lung cancer: acquired resistance to egfr tki therapy
-
44:03
egfr: the challenge of primary and secondary resistance
-
21:09
mechanisms of resistance to egfr tki and new treatment strategies
-
16:22
debate: drug of choice for exon 19 del egfr mutant nsclc - afatinib